Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alyssa M Roberts

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|August 8, 2025
Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosisSteven Tau, Malone Friedman, Alyssa M Roberts, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 5, 2026
GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort studyElaine J Ma, Alyssa M Roberts, Charlotte Y Jeong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 1, 2026
Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister CellsHuijuan Yang, Steven Tau, Andrew D McCray, et al.
The Journal of Investigative Dermatology|June 26, 2026
Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled TrialApril W Armstrong, Alyssa M Roberts, Gina Kostandy, et al.
JAMA Dermatology|June 24, 2026
Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical TrialApril W Armstrong, Alyssa M Roberts, Gina Kostandy, et al.
Cancers|June 26, 2025
Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast CancerAnneka L Johnson, Steven Tau, Austin M Sloop, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast CancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|August 8, 2025
Endocrine therapy induces oxidative stress in ER+ breast cancer that sensitizes persister cells to ferroptosisSteven Tau, Malone Friedman, Alyssa M Roberts, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 5, 2026
GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort studyElaine J Ma, Alyssa M Roberts, Charlotte Y Jeong, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 1, 2026
Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister CellsHuijuan Yang, Steven Tau, Andrew D McCray, et al.
The Journal of Investigative Dermatology|June 26, 2026
Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled TrialApril W Armstrong, Alyssa M Roberts, Gina Kostandy, et al.
JAMA Dermatology|June 24, 2026
Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical TrialApril W Armstrong, Alyssa M Roberts, Gina Kostandy, et al.
Cancers|June 26, 2025
Combined Radiation and Endocrine Therapies Elicit Benefit in ER+ Breast CancerAnneka L Johnson, Steven Tau, Austin M Sloop, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
Biorxiv : the Preprint Server for Biology|October 10, 2024
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast CancerNicole A Traphagen, Gary N Schwartz, Steven Tau, et al.
Cancer Research|January 8, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast CancerSteven Tau, Mary D Chamberlin, Huijuan Yang, et al.
Pageof 3